Clinical Trial Detail

NCT ID NCT03128619
Title Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Copanlisib + Letrozole + Palbociclib

Copanlisib + Letrozole

Age Groups: senior adult

Additional content available in CKB BOOST